Organovo (ONVO) versus Fibrocell Science (FCSC) Financial Comparison

Organovo (NASDAQ: ONVO) and Fibrocell Science (NASDAQ:FCSC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Profitability

This table compares Organovo and Fibrocell Science’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Organovo -881.93% -69.03% -63.00%
Fibrocell Science N/A -640.52% -100.12%

Risk & Volatility

Organovo has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Fibrocell Science has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Organovo and Fibrocell Science, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organovo 0 2 3 0 2.60
Fibrocell Science 0 0 3 0 3.00

Organovo presently has a consensus price target of $3.94, suggesting a potential upside of 261.24%. Fibrocell Science has a consensus price target of $5.00, suggesting a potential upside of 657.58%. Given Fibrocell Science’s stronger consensus rating and higher possible upside, analysts clearly believe Fibrocell Science is more favorable than Organovo.

Institutional and Insider Ownership

27.3% of Organovo shares are owned by institutional investors. Comparatively, 41.0% of Fibrocell Science shares are owned by institutional investors. 10.2% of Organovo shares are owned by company insiders. Comparatively, 2.1% of Fibrocell Science shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Organovo and Fibrocell Science’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Organovo $4.23 million 28.56 -$38.44 million ($0.36) -3.03
Fibrocell Science $350,000.00 48.84 -$15.29 million ($1.82) -0.36

Fibrocell Science has lower revenue, but higher earnings than Organovo. Organovo is trading at a lower price-to-earnings ratio than Fibrocell Science, indicating that it is currently the more affordable of the two stocks.

Summary

Fibrocell Science beats Organovo on 7 of the 13 factors compared between the two stocks.

About Organovo

Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

About Fibrocell Science

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply